Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
{{output}}
Large-cell neuroendocrine lung carcinoma (LCNEC) is a high-grade neoplasm with median survival of 1 year and limited therapeutic options. Here, we report the unusual case of a 47-yr-old female smoker with stage IV LCNEC featuring EML4-ALK variant 2 (E20:A20), ... ...
